Skip to content

Cardiomyopathy Familial Hypertrophic 4 Susceptibility To C2751427

Published: July 22, 2026Updated: August 20, 2026

A hereditary condition that increases susceptibility to heart muscle thickening. Affected individuals need regular cardiac monitoring and standard heart failure treatments.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
I78.0
ICD-11
BA00.0
Body system
cardiovascular
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Chest pain

!

Syncope

!

Heart failure

Chest discomfort or palpitations

(cardiovascular)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Palpitations

(cardiovascular)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Beta-adrenergic receptor blockers

First-line pharmacological therapy for HCM susceptibility, targeting symptom control through heart rate reduction and improved diastolic function. These agents also provide some protection against exercise-induced arrhythmias.

medication
2

Disease management and monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Disopyramide

Class Ia antiarrhythmic agent used for symptomatic outflow obstruction in HCM when beta-blockers are insufficient. It provides negative inotropic effects that reduce dynamic obstruction and improve exercise tolerance.

medication

Additional treatment options

Alcohol septal ablation

Minimally invasive procedure where ethanol is injected into the septal perforator artery to induce controlled infarction of the basal septum, reducing outflow obstruction in selected patients.

surgical

Implantable cardioverter-defibrillator evaluation

Risk stratification for sudden cardiac death and consideration of ICD placement in high-risk patients. ICD therapy is indicated for primary or secondary prevention based on established risk factors.

procedure

Annual cardiovascular assessment

Comprehensive yearly evaluation including ECG, echocardiography, and clinical symptom assessment. Includes family screening and genetic counseling to identify at-risk relatives.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Cardiomyopathy Familial Hypertrophic 4 Susceptibility To C2751427?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2733-2779.

guideline2014
2

Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242-255.

review2013
3

Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Engl J Med. 2011;364(17):1643-1656.

other2011
4

Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107(17):2227-2232.

review2003

Medication Comparisons

Compare medications used to treat Cardiomyopathy Familial Hypertrophic 4 Susceptibility To C2751427. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy